Aprea Therapeutics expands cancer trial after $30M private placement
What's the deal? Aprea Therapeutics (Nasdaq: APRE), a Doylestown, Pennsylvania-based biotech, is expanding enrolment in its lead cancer drug trial after closing an oversubscribed $30 million private placement. The company is developing APR-1051, a WEE1 inhibitor being tested in a Phase 1 study called ACESOT-1051 across several hard-to-treat cancers.
Two patients in the trial achieved partial responses, including one confirmed response in a uterine carcinosarcoma patient who saw a 50% reduction in target lesion size. Twenty-eight patients have received treatment so far, with stable disease observed in six additional patients.
Aprea plans to expand the study to include at least 50 uterine serous carcinoma patients and additional ovarian cancer patients.
Why now? The financing, completed on March 31, extends Aprea's cash runway into Q1 2028 — giving it roughly two years to generate enough clinical data to prove its drug works. Cash and equivalents jumped to $46.5 million from $14.6 million at the end of 2025.
Timing matters for another reason: additional clinical data is set for presentation on May 30 at the American Society of Clinical Oncology (ASCO) annual meeting, one of oncology's biggest stages.
“These efficacy results, coupled with the encouraging tolerability, support our precision medicine strategy and reinforce the potential of targeted therapies for patients who have limited treatment options,” chief executive officer Oren Gilad said.
What could go wrong? The trial is still in Phase 1, with dose escalation ongoing at the 300 mg cohort — meaning it is far from proving the drug's efficacy at scale. WEE1 inhibitors as a class have historically been dogged by severe toxicities; Aprea says it hasn't seen those issues yet, but the patient count remains small.
Meanwhile, the company has paused enrolment in its separate ABOYA-119 trial for ATR inhibitor ATRN-119 as a monotherapy, pivoting to explore combination strategies instead. That signals a narrowing of its pipeline focus.
Aprea reported a Q1 net loss of $3.3 million, or $0.22 per share, narrower than the $3.9 million loss a year earlier — but it remains a pre-revenue company burning cash.
The signal: Aprea's oversubscribed raise reflects sustained investor appetite for precision oncology — therapies designed around specific genetic mutations rather than broad tumour types. WEE1 inhibitors are an increasingly crowded space, but the tolerability profile Aprea is reporting could differentiate it if the data holds. For a late-stage biotech still pre-revenue, an ASCO presentation with promising early data and a freshly padded balance sheet is the playbook for building momentum toward later-stage trials — and potential partnership interest.
Read more: mychesco.com
